Idelalisib-Induced Pneumonitis in Chronic Lymphocytic Leukemia.

Ravi, Sasikanth N; Choi, Irene W; Ngapgue, Eva K; Stroiney, Amanda G; Miranda, Clive J.

Afiliación

Ravi SN; Pulmonology, Saint Peter's University Hospital, New Brunswick, USA.
Choi IW; Internal Medicine, Abrazo Community Health Network, Phoenix, USA.
Ngapgue EK; Internal Medicine, St. George's University School of Medicine, St. George's, GRD.
Stroiney AG; Internal Medicine, Saint Peter's University Hospital, New Brunswick, USA.
Miranda CJ; Internal Medicine, St. George's University School of Medicine, St. George's, GRD.

Cureus ; 16(5): e59541, 2024 May.

Article en En | MEDLINE | ID: mdl-38826911

ABSTRACT

Idelalisib, a phosphoinositide 3-kinase delta (PI3KÎ´) inhibitor, effectively treats relapsed chronic lymphocytic leukemia (CLL). While this targeted approach offers a therapeutic edge, particularly in B-cell malignancies, it is associated with complications such as pneumonitis. This report details idelalisib-induced pneumonitis, highlighting the importance of early diagnosis and tailored treatment in achieving a favorable patient outcome.

Palabras clave

b-cell chronic lymphocytic leukemia (b-cll); chronic lymphocytic leukemia (cll); drug induced pneumonitis; drug-induced interstitial lung disease (di-ild); hematology-oncology; idelalisib; mosaic; phosphoinositide 3-kinase (pi3k); progressive interstitial lung disease; tree-in-bud